<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928407</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 040-DATA</org_study_id>
    <nct_id>NCT01928407</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts</brief_title>
  <acronym>DATA</acronym>
  <official_title>A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir,Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-naïve Subjects With CD4counts Below 200 µL.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase IV, prospective, multicenter , randomized open label, 48 weeks study to evaluate the
      antiretroviral efficacy and safety of atazanavir/ritonavir or darunavir/ritonavir, each in
      combination with a fixed dose of tenofovir disoproxil fumarate- emtricitabine in
      HIV-1-infected treatment-naïve subjects with CD4 counts below 200 µL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Principal objective

      To evaluate the virological efficacy and safety at week 48 of 2 regimens atazanavir/ritonavir
      (ATZ/r) 300/100 mg or darunavir/ritonavir (DRV/r) 800/100 mg, each in combination with a
      fixed-dose of tenofovir/emtracitabine in HIV-1 treatment-naïve subjects with CD4 counts below
      200 µL.

      Secondary objectives

        -  Proportion of subjets with virologic efficacy at week 24

        -  Proportion of subjects with confirmed virologic failure at week 24 or later

        -  Proportion of patients with virologic mutations

        -  Evaluate the virologic effect in seminal fluid

        -  To evaluate immunological response over time up to week 48

        -  To assess plasma and seminal pharmacokinetics of the drugs in the treatment regimen at
           week 4, 24, and 48

        -  Correlate the pharmacokinetic properties of the drugs with virologic outcome in plasma
           and semen at week 4 and 48

        -  Correlate the free fraction (not bound to protein) of atazanavir and darunavir in plasma
           and semen to virologic outcome

        -  Evaluate the relationship of bilirubinemia with atazanavir

        -  Change from baseline in fasting lipids, fasting glucose and insulin over time in the 2
           arms

        -  Compare adherence patient satisfaction and sexual behaviour between the regimens

      Methodology

      This is a 48 week, multicentre, prospective, open label, phase IV, randomized. non
      comparative, study.

      Inclusion criteria

        -  Male or female, aged &gt; 18 years of age.

        -  HIV-1 infection determined by a positive ELISA and confirmed by Western blot

        -  Plasma HIV-RNA &gt; 1 000 c/mL

        -  CD4+T cell count &lt; =200 cells/mm3 at the time of screening, or &lt; =250 cells/mm3 if the
           CD4 count was &lt;200 cells/mm3 12 weeks before screening.

        -  Women of childbearing potential must agree to use an effective method of barrier
           contraception or have documented sterility.

        -  Subjects must have medical insurance throught the Securite Sociale

        -  Ability to understand and provide written informed consent.

      Non-inclusion criteria

        -  Acute opportunistic infection within the past two weeks

        -  HIV-2 infection

        -  pregnant woman

        -  Any subject with drug resistance mutations at screening

        -  Any subject with a grade 3 or greater clinical or laboratory adverse event at screening

        -  Any subject who has received antiretoviral therapy except for prevention of mother to
           child transmission and patients who has received post exposure prophylaxis for a a month
           or less

        -  calculated creatinine clearance &lt; 60/mL as estimated by the Cockcroft- Gault equation

        -  Patients in the opinion of the investigator that are unlikley to be able to follow study
           instructions

        -  Any subject unable to take antiretroviral medication for whatever reason

        -  Any subject taking a treatment or medication that is contraindicated when
           co-administered with any arm or drug in the treatment.

      Treatment:

        -  Group 1 : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if TDF/FTc contre-indicated

        -  atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg by day, 3 pills once a day,
           during 48 weeks during a meal

        -  Group 2 : DRV+ TDF/FTC (or ABC/3TC if TDF/FTc contre-indicated)

        -  darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg by day, 4 pills once a day,
           during 48 weeks during a meal

      Primary Endpoints :

        -  Proportion of patients with HIV-1 plasma viral load below 50 copies/mL at week 48 while
           receiving their initial regimen

        -  Proportion of patients experiencing grade 2-4 adverse clinical and laboratory events
           including hematology, chemistry, lipids (total cholesterol, HDL cholesterol, LDL
           cholesterol, triglycerides), glucose and insulin by week 48.

      Secondary endpoints:

        -  Proportion of patients with plasma HIV RNA below 50 cp/mL at week 24

        -  Proportion of patients with HIV RNA&gt; 50 cp/mL at week 24 or later confirmed by a second
           HIV RNA at least 14 days after the first test

        -  Development of resistance mutations in subjects who have virologic failure testing at 24
           weeks or later tested by a genotypic resistance test

        -  Evaluate the virologic effect in seminal fluid at baseline, W4 and W48 by change in HIV
           RNA concentrations in semen over time

        -  To evaluate immunological response over time up to week 48 in the 2 arms by CD4 cell
           count ( W-4, W2,W4, W12, W36 and W48), differenciation and activation in T CD4 ( W2,W4,
           W12, W24 and W48); Change in lymphocyte subset reconsistution at week 48 compared to
           baseline. ; Change in immunolgic markers of inflammations at weeks 2, 4, 12, 24, 48

        -  To assess plasma and seminal pharmacokinetics of the drugs in the treatment regimen at
           week 4, 24, and 48 through residual concentrations ( C min) of antiretroviral drugs at
           W4, W24, and W48

        -  Atazanavir and darunavir (plasma and seminal) drug concentrations and coorelation with
           adverse clinical and laboratory events.

        -  Evaluate the relationship of bilirubinemia with atazanavir pharmacokinetics (Cmin)

        -  Evolution of lipid, glucose and insulin parameters from baseline to weeks 24 and 48

        -  Adherence to regimen, patient satisfaction and sexual behaviour between the regimens at
           W2,W24 and W48 mesured by ( mettre ref)

        -  Evolution of anthropomorphic measurements from baseline to weeks 24, 48.

      Substudies Brief description (2 lines maximum) and person in charge of the substudy

        -  Immunologic substudy ( Pr Brigitte Autran) : Change in immunolgic markers of
           inflammations at weeks 2, 4, 12, 24, 48 and change in lymphocyte subset reconsistution
           at week 48 compared to baseline.

        -  Pharmacologic substudy ( Dr Gilles Peytavin) : To assess plasma and seminal
           pharmacokinetics of the drugs in the treatment regimen at week 4, 24, and 48 through
           residual concentrations ( C min) of antiretroviral drugs at W4, W24, and W48

        -  Virologic substudy ( Dr Anne Geneviève Marcelin) : Evaluate the virologic effect in
           seminal fluid at baseline, W4 and W48

        -  Behaviour substudy ( Dr France Lert) : Compare adherence patient satisfaction and sexual
           behaviour between the regimens at W2,W24 and W48

      Estimated enrolment: 120 subjects (60 per group) randomly assigned 1:1
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2011</start_date>
  <completion_date type="Actual">January 7, 2013</completion_date>
  <primary_completion_date type="Actual">March 29, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load of HIV-1 &lt; 50 cp/ml</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the virological efficacy and safety at week 48 of 2 regimens atazanavir/ritonavir (ATZ/r) 300/100 mg or darunavir/ritonavir (DRV/r) 800/100 mg, each in combination with a fixed-dose of tenofovir/emtracitabine in HIV-1 treatment-naïve subjects with CD4 counts below 200 µL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Proportion of subjets with virologic efficacy</measure>
    <time_frame>24 weeks</time_frame>
    <description>• Proportion of subjets with virologic efficacy (viral load of HIV-1 &lt;50 cp/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Proportion of subjects with confirmed virologic failure</measure>
    <time_frame>24 weeks</time_frame>
    <description>• Proportion of subjects with confirmed virologic failure (viral load &gt; 50 cp/ml on 2 consecutive mesures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral lod of HIV-1 on seminal fluid</measure>
    <time_frame>W00,W4 et W48</time_frame>
    <description>• Evaluate the viral load of HIV-1 at week 0, week 4 and week 48 on the seminal fluid (substudy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic response</measure>
    <time_frame>W-4,W2,W4,W12,W24 and W48</time_frame>
    <description>• Evaluate the immunologic response by the CD4 mesearement at W-4,W2,W4,W12,W24 and W48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differenciation and activation of lymphocytes</measure>
    <time_frame>W0,W2,W4,W12,W24 and W48</time_frame>
    <description>At the end of the study, in a central lab, we will measure some inflammation and activation markers (CD69, HLA-DR, CD38, annexine V, IL-6, CD14s, IL-7 plasma) of lymphocytes CD4 and CD8(with the plasmatheque collected during the study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics evaluation of the drugs in plasma</measure>
    <time_frame>W4,W24 and W48</time_frame>
    <description>Measure of drugs (atazanir and darunavir) concentration (24 hours after taking treatment)in plasma at week 4, 24, and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation of the drugs in semen</measure>
    <time_frame>W4 and W48</time_frame>
    <description>Measure of drugs (atazanir and darunavir) concentration (24 hours after taking treatment)in semen at week 4 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Evaluate the relationship of bilirubinemia with atazanavir</measure>
    <time_frame>W4 and W48</time_frame>
    <description>Evaluate the relationship of the evolution of the measure of bilirubinemia (collected during study) with the concentration of atazanavir in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose, lipids and insulin</measure>
    <time_frame>W48</time_frame>
    <description>• Change from baseline in fasting lipids, fasting glucose and insulin over time in the 2 arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinic and biologic tolerance</measure>
    <time_frame>W48</time_frame>
    <description>Evaluate the clinic and biologic tolerance between the 2 regimens (adverse event and some biologic measure will be collected for this evaluation).
We will see in two arms if there are more adverse event or biological event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual behaviour</measure>
    <time_frame>W0,W24 et W48</time_frame>
    <description>• Compare sexual behaviour between the regimens (substudy with a questionnary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence patient satisfaction</measure>
    <time_frame>W2,W24 et W48</time_frame>
    <description>• Compare adherence patient satisfaction between the regimens (with questionnary)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>Immunosuppression-related Infectious Disease</condition>
  <arm_group>
    <arm_group_label>ATAZANAVIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DARUNAVIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DARUNAVIR</intervention_name>
    <description>The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules</description>
    <arm_group_label>DARUNAVIR</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATAZANAVIR</intervention_name>
    <description>The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules</description>
    <arm_group_label>ATAZANAVIR</arm_group_label>
    <other_name>REYATAZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female, aged &gt; 18 years of age

          -  HIV-1 infection determined by a positive ELISA and confirmed by Western blot

          -  Plasma HIV-RNA &gt; 1 000 c/mL

          -  CD4+T cell count &lt; =200 cells/mm3 at the time of screening, or &lt; =250 cells/mm3 if the
             CD4 count was &lt;200 cells/mm3 12 weeks before screening

          -  Women of childbearing potential must agree to use an effective method of barrier
             contraception or have documented sterility

          -  Subjects must have medical insurance throught the Securite Sociale

          -  Ability to understand and provide written informed consent

        Exclusion Criteria

          -  Acute opportunistic infection within the past two weeks

          -  HIV-2 infection

          -  Pregnant woman

          -  Any subject with drug resistance mutations at screening

          -  Any subject with a grade 3 or greater clinical or laboratory adverse event at
             screening

          -  Any subject who has received antiretoviral therapy except for prevention of mother to
             child transmission and patients who has received post exposure prophylaxis for a a
             month or less

          -  Calculated creatinine clearance &lt; 60/mL as estimated by the Cockcroft- Gault equation

          -  Patients in the opinion of the investigator that are unlikley to be able to follow
             study instructions

          -  Any subject unable to take antiretroviral medication for whatever reason

          -  Any subject taking a treatment or medication that is contraindicated when
             co-administered with any arm or drug in the treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence LS SLAMA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital TENON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland RL LANDMAN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Zobda Quitman</name>
      <address>
        <city>Fort De France</city>
        <state>Martinique</state>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Raymond Poincare</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.D de Vendee</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte-Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Melun</name>
      <address>
        <city>Melun</city>
        <zip>77011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital L'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Jean Roussillon</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Rene Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.R.A</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gustave Dron</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2013</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>naives, CD4 &lt; 200 cell/mm3, Atazanavir, Darunavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

